



0300

00230

#3

FIRST CLASS MAIL CERTIFICATE

I hereby certify that this document is being deposited with the United States Postal Service on this date as first class mail addressed to: Commissioner of Patents and Trademarks, United States Patent and Trademark Office, Washington, D.C. 20231.

Linda O. Palladino
Linda O. Palladino

July 27, 2000
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application Of : Wong, et. al.
USSN : 09/577,468
Filed : May 24, 2000
For : USE OF MODIFIED CILIARY
NEUROTROPHIC FACTOR
Examiner : Not yet known
Group : Not yet known

July 27, 2000

Commissioner for Patents
U.S. Patent and Trademark Office
Washington, D.C. 20231

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §1.97(c) AND 1.98

SIR:

Submitted herewith is PTO Form 1449 to make of record those references of which Applicant is aware which may be pertinent to an examination of the captioned patent application on the merits. Copies of the listed references are enclosed.



No fee is deemed necessary for filing this paper. However, if any fee is required, the Commissioner is hereby authorized to charge any such fee to Deposit Account No. 18-0650.

Respectfully submitted,

Linda O. Palladino

Gail M. Kempler
Reg. No. 32,143
Joseph M. Sorrentino
Reg. No. 32,598
Attorneys for Applicants
Linda O. Palladino
Reg. No. 45,636
Patent Agent for Applicants
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591
(914) 345-7400



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

July 27, 2000

Examiner Initials	Patent Number	Patent Date	Name	Class/ Subclass	Filing Date
_____	_____	_____	_____	_____	_____

[illegible]



OTHER DOCUMENTS

Examiner
Initials

- ____ NEUROLOGY, issued 1996, Group A.C.T.S., "A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis", pp. 1244-1249.
- ____ PROC. NATL. ACAD. SCI., Volume 94, issued 1997, Gloaguen, I., et al., Ciliary neurotrophic factor corrects obesity and diabetes associated with leptin deficiency and resistance", pp. 6456-6461.
- ____ BIOCHEMISTRY, Volume 33, issued 1994, Panayotatos, N., et al., "Recombinant Human CNTF Receptor α : Production, Binding Stereochemistry, and Characterization of Its Activity as a Diffusible Factor", pp. 5813-5818.
- ____ J. BIOL. CHEM., Volume 268, issued 1993, Panayotatos, N., et al., "Exchange of a Single Amino Acid Interconverts the Specific Activity and Gel Mobility of Human and Rat Ciliary Neurotrophic Factors", pp. 19000-19003.
- ____ NATURE GEN, Volume 14, issued September 14, 1996, Vaisse, C., et al., "Leptin activation of Stat3 in the hypothalamus of wild-type and *ob/ob* mice but not *db/db* mice", pp. 95-97.



EXAMINER
CONSIDERED

DATE

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Respectfully submitted,

By:

A handwritten signature in cursive script that reads "Linda O. Palladino".

Gail Kempler

Reg. No. 32,143

Joseph M. Sorrentino

Reg. No. 32,598

Attorneys for Applicant

Linda O. Palladino

Reg. No. 45,636

Patent Agent for Applicant

Regeneron Pharmaceuticals, Inc.

777 Old Saw Mill River Road

Tarrytown, New York 10591

(914) 345-7400